Apricell Biotechnology

What Apricell Biotechnology does

Apricell Biotechnology Inc. is a Canadian private biotechnology company founded in 2021 and based in Victoria, British Columbia, that develops and commercializes hydrogel-based 3D tissue culture platforms used to generate spheroids and organoids for cancer research and preclinical drug testing. Its core product portfolio consists of three proprietary platforms: the 3-in-1™ insert for six-well plates that combines spheroid formation, ECM integration, drug testing, and downstream analysis (including in-situ IHC and paraffin embedding) without model transfers; the TruSphere™ microwell array platform available in 6/12/24-well formats that produces up to 3,500 uniform spheroids per plate from a single pipetting step; and the HTSphere™ 96-well plate platform that produces up to 1,152 spheroids per plate and is compatible with automated cell dispensing and standard imaging equipment.

The company monetizes through two streams: direct hardware sales of its proprietary culture plates to academic and pharmaceutical researchers, and a fee-for-service offering branded Apricell Plus™, which delivers end-to-end 3D cancer model creation, assay execution (viability, cytotoxicity, proliferation, immuno-infiltration), and data analysis as contract research. Products are sold globally via the company website on a quote-based pricing model, with orders routed through Google Forms and fulfillment from a Canadian warehouse. Customer segments are split between pharmaceutical and biotech companies conducting preclinical drug screening (primary) and academic and research institutions using the platforms for cancer biology research and organoid development (primary), with oncology and personalized-medicine researchers identified as a secondary use-case segment.

Commercially, Apricell operates with 1–10 employees, a PhD-heavy leadership team, and no publicly disclosed equity funding rounds; its growth to date has been supported by non-dilutive Canadian programs (NRC-IRAP, Mitacs) and co-development partnerships with the University of Calgary and the University of Victoria. Marketing relies on scientific conference participation (including SLAS2026), content and resource libraries on the company website, and a "Talk With Our Expert" consultative sales motion aimed at enterprise accounts. The company is founder-led under CEO Dr. Amir Seyfoori, with CTO Dr. Amir Reza Aref and CCO Dr. Rashmi Rajendra rounding out the executive team.

Name

Apricell Biotechnology

Legal name

Apricell Biotechnology Inc.

Website

https://apricell.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Apricell Biotechnology is a Canadian private biotech that develops and sells proprietary hydrogel-based 3D tissue culture platforms (3-in-1™, TruSphere™, HTSphere™) and Apricell Plus™ contract research services for generating spheroids and organoids used in cancer research and preclinical drug testing by pharmaceutical, biotech, and academic customers globally.

Ownership category

akta.pro rank

Product category

3D Cell Culture Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Laboratory Consumables & Plasticware (Tips, Tubes, Plates, Filters) (HLAGAIAH)

Keywords

• 3D cell culture platforms
• Organoid drug screening
• Preclinical cancer models
• Hydrogel microwell arrays
• Contract research services

Headquarters

HQ city

Victoria

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Hardware Sales - 3D Culture Plates: Sale of proprietary hydrogel-based culture plate inserts and platforms (3-in-1, TruSphere, HTSphere) to academic and pharmaceutical researchers for 3D cell culture and drug screening applications.
2. Contract Research Services (Apricell Plus): Fee-for-service preclinical 3D cell-based assay solutions including model creation, assay execution, and data analysis. Targets pharmaceutical companies requiring drug efficacy testing, toxicology studies, and disease modeling services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Apricell Biotechnology designs and manufactures proprietary hydrogel-based 3D tissue culture microwell array platforms (3-in-1™, TruSphere™, HTSphere™) that enable high-throughput formation of uniform spheroids and organoids for cancer research and drug screening. The company also provides Apricell Plus™, a contract research service that uses these proprietary plates to deliver physiologically relevant 3D cancer models and preclinical assays for pharmaceutical and academic customers.

Product overview

Apricell Biotechnology offers a portfolio of three core hydrogel-based 3D tissue culture platforms designed for organoid and spheroid generation: the 3-in-1™ Platform for complex in vitro tissue microenvironment models, the TruSphere™ Platform for large-scale uniform spheroid/organoid generation, and the HTSphere™ Platform for high-throughput drug screening applications. These platforms are complemented by Apricell Plus™, a contract research service powered by the proprietary HTSphere™ and TruSphere™ technologies, enabling researchers and pharmaceutical companies to access advanced 3D cancer models and assay services without internal platform procurement.

Differentiator

Problem solved

Functional benefit

Brands

• Apricell Plus™: Contract research services powered by advanced 3D cancer models, providing a full-service platform for preclinical testing using proprietary HTSphere™ and TruSphere™ Plates.

Products and services

• 3-in-1™ Platform Hydrogel-based 3D tissue culture system that fits within each well of a six-well plate, combining spheroid formation, ECM integration, drug testing, and downstream analysis in a single insert. Produces 24 spheroids per insert (144 per six-well plate) with size range 200-500 micrometers and supports co-cultures, tri-cultures, invasion studies, and immunohistochemistry analysis for academic and pharmaceutical researchers.
• TruSphere™ Platform Hydrogel-based 3D tissue culture microwell array system for rapid, uniform generation of spheroids and organoids from a single pipetting step. Available in 6-, 12-, or 24-well plate formats, producing 100-600 uniform spheroids per insert (up to 3,500 per plate) with microwell diameters of 300, 500, or 700 micrometers. Designed for academic and pharmaceutical researchers performing assays with standard laboratory imaging equipment.
• HTSphere™ Platform High-throughput 3D tissue culture platform featuring a microwell array integrated within each well of a standard 96-well plate, producing 6-12 uniform spheroids per well (up to 1,152 per plate). Enables multiplexed co-culture and ECM embedding in a single plate and is compatible with automated cell dispensing systems and standard lab imaging equipment for high-throughput drug screening applications.
• Apricell Plus™ Full-service contract research platform that uses proprietary HTSphere™ and TruSphere™ plates to deliver physiologically relevant 3D cancer models for drug efficacy testing, toxicology, and disease modeling. Follows a four-step workflow from cell sourcing through 3D model creation, assay execution, and data analysis and reporting, including image-based cellular screening, cell viability and cytotoxicity assays, cell proliferation assays, and 3D immuno-infiltration assays for pharmaceutical and biotech customers.

Quantifiable outcome

• 3-in-1 Platform produces 144 spheroids per six-well plate; TruSphere produces up to 3500 spheroids per plate; HTSphere produces up to 1152 spheroids per 96-well plate

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• University of CalgarycoreStrategic or Co-development PartnerCollaborative research partner in developing the Organoid-on-a-Plate technology. University of Calgary logo appears in "Our Supporters" section indicating ongoing research and development collaboration.
• University of VictoriacoreStrategic or Co-development PartnerCollaborative research partner in technology development. UVic logo appears in "Our Supporters" section indicating ongoing R&D partnership.

Scale indicators1 record

Recent moves1 record

Expansion highlights5 records

Direct peers

• Mimetas: Develops organ-on-chip and microfluidic 3D tissue models for preclinical drug screening; comparable to Apricell in selling physiologically relevant in vitro models to pharma R&D.
• Emulate Inc. Organ-on-chip platform company targeting pharma preclinical applications with standardized, human-relevant in vitro models, overlapping Apricell's positioning in predictive drug-response testing.
• SUN Bioscience: Swiss developer of the Gri3D organoid plate platform, one of the closest direct analogs to Apricell's microwell-array plates for standardized organoid culture and screening.
• InSphero: Specialist in 3D spheroid and organoid models for drug discovery and toxicology, offering both plate-based products and contract research services that closely mirror Apricell's hardware-plus-services model.

Broad incumbents

• Corning Life Sciences: Major life-sciences consumables manufacturer whose Matrigel, spheroid microplates, and 3D culture products compete directly with Apricell's hydrogel plate portfolio across pharma and academic customers.
• Thermo Fisher Scientific: Global life-sciences tools incumbent offering Gibco 3D culture media, Nunclon spheroid plates, and a wide organoid product line; competes with Apricell on catalog presence and pharma supply agreements.

Regional players

• STEMCELL Technologies: Canadian-headquartered life-sciences tools company offering 3D culture media, organoid kits, and related consumables; competes regionally and through shared academic distribution channels.

Emerging players

• Cellesce: Welsh biotech focused on scalable organoid expansion technology, overlapping with Apricell on standardized organoid production for drug discovery and biomedical research.
• DefiniGEN: Provides iPSC-derived organoid models (notably liver) and disease modeling services to pharma; overlaps with Apricell's oncology-focused organoid services and hardware offerings.
• QGel Bio: Swiss developer of synthetic hydrogel matrices for 3D cell culture and organoid applications; comparable to Apricell in addressing limitations of traditional matrices like Matrigel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/apricell-biotechnology-inc
• Instagraminstagram.com/apricell_biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apricell Biotechnology